LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2017
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Cognition disorders
- Focus Pharmacodynamics
- 11 May 2016 Status changed from recruiting to withdrawn prior to enrolment as funding not obtained.
- 22 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 26 Nov 2013 New trial record